A detailed history of Vanguard Group Inc transactions in Celcuity Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 828,597 shares of CELC stock, worth $13.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
828,597
Previous 820,776 0.95%
Holding current value
$13.1 Million
Previous $12 Million 49.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$13.74 - $21.6 $107,460 - $168,933
7,821 Added 0.95%
828,597 $17.9 Million
Q4 2023

Feb 14, 2024

BUY
$8.7 - $15.02 $253,874 - $438,298
29,181 Added 3.69%
820,776 $12 Million
Q3 2023

Nov 14, 2023

BUY
$8.96 - $10.75 $83,910 - $100,673
9,365 Added 1.2%
791,595 $7.24 Million
Q2 2023

Aug 14, 2023

BUY
$9.39 - $12.18 $641,506 - $832,113
68,318 Added 9.57%
782,230 $8.59 Million
Q1 2023

May 15, 2023

BUY
$9.4 - $12.82 $2.66 Million - $3.63 Million
283,424 Added 65.84%
713,912 $7.32 Million
Q4 2022

Feb 10, 2023

SELL
$7.55 - $14.01 $89,520 - $166,116
-11,857 Reduced 2.68%
430,488 $6.03 Million
Q3 2022

Nov 14, 2022

SELL
$8.0 - $10.64 $8,000 - $10,640
-1,000 Reduced 0.23%
442,345 $4.44 Million
Q2 2022

Aug 12, 2022

SELL
$5.35 - $10.11 $262,101 - $495,299
-48,991 Reduced 9.95%
443,345 $4.03 Million
Q1 2022

May 13, 2022

SELL
$7.93 - $13.33 $872 - $1,466
-110 Reduced 0.02%
492,336 $4.6 Million
Q4 2021

Feb 14, 2022

SELL
$11.96 - $19.35 $3,887 - $6,288
-325 Reduced 0.07%
492,446 $6.5 Million
Q3 2021

Nov 12, 2021

BUY
$17.35 - $24.87 $993,148 - $1.42 Million
57,242 Added 13.14%
492,771 $8.87 Million
Q2 2021

Aug 13, 2021

BUY
$14.25 - $30.93 $6.21 Million - $13.5 Million
435,529 New
435,529 $10.5 Million

Others Institutions Holding CELC

About Celcuity Inc.


  • Ticker CELC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,941,300
  • Market Cap $236M
  • Description
  • Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...
More about CELC
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.